Glaucoma: The Silent Thief of Sight – Understanding, Diagnosis, and Research

Around 400,000 people in Spain may be living with glaucoma without knowing it, highlighting the critical importance of regular eye examinations, particularly for those over 45. This underscores the need for increased awareness and early detection efforts for this potentially blinding disease.

What is Glaucoma?

Glaucoma is a group of diseases that cause progressive and irreversible damage to the optic nerve, which connects the eye to the brain. It is a leading cause of blindness worldwide, according to the World Health Organization (WHO). The most common form, open-angle glaucoma, often progresses without noticeable symptoms in its early stages.

The damage typically results in a progressive loss of peripheral vision, often described as tunnel vision, impacting daily activities like driving, reading, and safe navigation.

The Scope of Glaucoma in Spain

It is estimated that approximately 1.1 million people in Spain suffer from some form of glaucoma. Alarmingly, around 40 percent of those affected are unaware of their condition due to the insidious, symptomless progression of the disease in its initial phases. Diagnosis often occurs after significant and irreversible vision loss has already taken place.

Current Treatments and Management

While there is currently no cure for glaucoma, treatments such as eye drops, laser procedures, and surgical interventions can effectively unhurried or halt the progression of the disease when detected early and adhered to consistently.

Glaucoma and Disability

The impact of glaucoma extends beyond vision loss, often affecting a person’s autonomy and quality of life. More than half of those diagnosed with glaucoma in Spain have a recognized disability, with a significant proportion – approximately 55.6 percent – having a disability degree exceeding 65 percent. Around 379,000 people diagnosed with glaucoma in Spain have some degree of recognized disability, representing about 58 percent of patients.

The Need for Early Diagnosis

Joaquín Carratalá, president of the Glaucoma Association for Sufferers and Families (AGAF), describes glaucoma as “the silent thief of vision” because it progresses without symptoms in its early stages. Many individuals only discover they have the condition after experiencing irreversible vision loss.

Push for Neurodegenerative Disease Recognition

AGAF is advocating for the official recognition of glaucoma as a neurodegenerative disease. This classification, they argue, would stimulate new research focused on regenerating nerve cells in the retina and optic nerve, potentially leading to future treatments capable of restoring lost vision. The damage caused by glaucoma directly affects the nerve cells of the retina and optic nerve.

AGAF’s Role and Support

Founded in 2005 and declared of public utility in 2011, AGAF is a non-profit organization dedicated to supporting individuals affected by glaucoma, disseminating accurate information, and promoting research. AGAF emphasizes that seeking support from the time of diagnosis can significantly improve a patient’s experience and outcomes, rather than waiting until significant vision loss occurs.

For more information and support, visit the AGAF website.